Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 24, 2017
Pharmacy Choice - Pharmaceutical News - Genomic Health Announces Favorable Draft Local Coverage Determination LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score in... - July 24, 2017

Pharmacy News Article

 5/19/17 - Genomic Health Announces Favorable Draft Local Coverage Determination LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score in...

Genomic Health Announces Favorable Draft Local Coverage Determination LCD on Medicare Coverage for Use of Oncotype DX Genomic Prostate Score in Patients with Favorable Intermediate-risk Prostate Cancer

By a News Reporter-Staff News Editor at Insurance Weekly News Genomic Health, Inc. (Nasdaq: GHDX) announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX Genomic Prostate Score? (GPS). The draft LCD recommends Medicare coverage for use of the test in qualified patients with favorable intermediate-risk prostate cancer throughout the United States.

"This positive draft local coverage determination represents an important step toward ensuring that prostate cancer patients covered by Medicare have access to the unique biological information provided by Oncotype DX to more precisely assess both the current state and future risk of their cancer to better inform the management of their disease," said Phil Febbo, M.D., chief medical officer, Genomic Health.

Once the draft LCD on Medicare coverage for intermediate-risk patients is finalized, an estimated 30,000 additional men will have further access to the test to help them more confidently decide between active surveillance or immediate intervention. This adds to the existing 50,000 low-risk patients that have been covered by Medicare since 2015 and brings the total number of Medicare patients eligible for GPS coverage to 80,000.

The draft LCD is HYPERLINK "https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=37261&ContrId=377&ver=3&ContrVer=1&CntrctrSelected=377*1&Cntrctr=377&name=&DocType=AllProposed&s=34%7c48%7c53%7c58&bc=AggAAAQAAAAAAA%3d%3d&" \nposted to the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website. It will go through Medicare's review process, which includes a public comment period, finalization and notification. Once final, LCDs are subject to annual review by the MACs and, as such, Genomic Health will continue to generate scientific data and publications to demonstrate enhanced clinical utility of the GPS.

Keywords for this news article include: Genetics, Medicare, Oncology, Epidemiology, Health Policy, Prostate Cancer, Genomic Health Inc., Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC



(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 24: What's New? New Treatments for Type 2 Diabetes
Last Chance
Jul 25: Smoking Cessation: A Toolkit for Pharmacy Professionals
Jul 26: Management of Schizophrenia & Acute Agitation
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415